Ebola Treatment Trial Begins Amid DRC Outbreak

On July 2, 2026, the World Health Organization declared that the first patient had been enrolled in a new clinical trial targeting the Bundibugyo strain of Ebola virus in the eastern Democratic Republic of Congo. The trial marks a critical step in the global effort to curb an outbreak that has already resulted in 1,406 confirmed cases and 438 deaths, according to WHO data released on June 30.

The virus, which spreads through direct contact with bodily fluids, has proven especially lethal, and there are currently no approved vaccines or treatments for this particular strain. The study is jointly coordinated by the Institut National de Recherche Biomédicale in the DRC, the Institute of Tropical Medicine in Belgium, and the University of Oxford in the United Kingdom. WHO Director‑General Tedros Adhanom Ghebreyesus emphasized that while patients have survived without approved therapeutics, the availability of safe and effective medicines could dramatically reduce mortality.

Two investigational treatments are being tested. The first, remdesivir, is a broad‑acting antiviral originally approved for COVID‑19, which laboratory studies suggest may interfere with Ebola replication. The second, MBP134, is an experimental combination of monoclonal antibodies engineered to neutralize multiple Ebola viruses, including the Bundibugyo variant. All trial participants receive the best standard supportive care, while the study assigns them randomly to receive remdesivir, MBP134, both agents, or neither, to assess each therapy’s impact on 28‑day survival.

Researchers anticipate that a few hundred participants may be sufficient if one drug shows strong efficacy, but they have prepared for enrollment of up to 1,000 patients to ensure robust results. The trial is currently limited to a single treatment center in Ituri province, an area challenged by ongoing conflict and insecurity that threatens health‑care delivery. Plans exist to expand to additional sites once safety and logistical conditions improve.

Funding for the study includes donations of both therapeutics—remdesivir from Gilead Sciences and MBP134 from the U.S. government, which also finances antibody development. If successful, the treatments could become part of the standard response toolkit for future Ebola outbreaks, offering a beacon of hope for affected communities.

WHO officials continue to stress the importance of early detection, rapid isolation, and supportive care in managing Ebola cases. The trial’s progress will be closely monitored, and interim results may guide immediate treatment recommendations while longer‑term outcomes shape global preparedness strategies.